Indeloxazine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Indeloxazine
Indeloxazine.svg
Clinical data
ATC code
  • None
Legal status
Legal status
  • Discontinued
Identifiers
Synonyms CI-874, YM-08054
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C14H17NO2
Molar mass 231.290 g/mol
3D model (Jmol)
  (verify)

Indeloxazine (INN) (Elen, Noin), or indeloxazine hydrochloride (USAN, JAN), is an antidepressant and cerebral activator[1][2] that was marketed in Japan and South Korea by Yamanouchi Pharmaceutical Co., Ltd for the treatment of psychiatric symptoms associated with cerebrovascular diseases, namely depression resulting from stroke, emotional disturbance, and avolition.[3][4] It was marketed from 1988[4] to 1998, when it was removed from the market reportedly for lack of effectiveness.[5]

Indeloxazine acts as a serotonin releasing agent, norepinephrine reuptake inhibitor, and NMDA receptor antagonist.[6][7] It has been found to enhance acetylcholine release in the rat forebrain through activation of the 5-HT4 receptor via its action as a serotonin releasing agent.[8][9][10] The drug has been found to possess nootropic,[11][12] neuroprotective,[13][14][15][16] anticonvulsant,[17] and antidepressant-like effects in animal models.[1][6]

References[edit]

  1. ^ a b Kojima T, Niigata K, Fujikura T, et al. (September 1985). "Syntheses of (+/-)-2-[(inden-7-yloxy)methyl]morpholine hydrochloride (YM-08054, indeloxazine hydrochloride) and its derivatives with potential cerebral-activating and antidepressive properties". Chemical & Pharmaceutical Bulletin. 33 (9): 3766–74. PMID 4092278. doi:10.1248/cpb.33.3766. 
  2. ^ Hayes AG, Chang T (January 1983). "Determination of indeloxazine, a new antidepressant agent, in human plasma by gas-liquid chromatography with electron-capture detection". Journal of Chromatography. 272 (1): 176–80. PMID 6841538. doi:10.1016/s0378-4347(00)86115-0. 
  3. ^ Index nominum, international drug ... - Google Books. 2000. ISBN 978-3-88763-075-1. 
  4. ^ a b r Ganellin, C; j Triggle, D; MacDonald, F. (1997). Dictionary of pharmacological agents - Google Books. ISBN 978-0-412-46630-4. 
  5. ^ Hayashi, K; Hashimoto, K; Yanagi, M; Umeda, T; Hama, R (8 August 1998). "Drug approval in Japan questioned.". Lancet. 352 (9126): 491. PMID 9708787. doi:10.1016/s0140-6736(05)79232-1. 
  6. ^ a b Yamaguchi T, Ohyama M, Suzuki M, et al. (September 1998). "Neurochemical and behavioral characterization of potential antidepressant properties of indeloxazine hydrochloride". Neuropharmacology. 37 (9): 1169–76. PMID 9833647. doi:10.1016/s0028-3908(98)00009-4. 
  7. ^ Kaneko S, Sugimura M, Inoue T, Satoh M (June 1991). "Effects of several cerebroprotective drugs on NMDA channel function: evaluation using Xenopus oocytes and [3H]MK-801 binding". European Journal of Pharmacology. 207 (2): 119–28. PMID 1652446. doi:10.1016/0922-4106(91)90086-w. 
  8. ^ Peñas-Cazorla, Raúl; Vilaró, M. Teresa (2014). "Serotonin 5-HT4 receptors and forebrain cholinergic system: receptor expression in identified cell populations". Brain Structure and Function. 220 (6): 3413–3434. ISSN 1863-2653. doi:10.1007/s00429-014-0864-z. 
  9. ^ Yamaguchi T, Suzuki M, Yamamoto M (December 1997). "Facilitation of acetylcholine release in rat frontal cortex by indeloxazine hydrochloride: involvement of endogenous serotonin and 5-HT4 receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 356 (6): 712–20. PMID 9453456. doi:10.1007/pl00005110. 
  10. ^ Yamamoto M, Takahashi K, Ohyama M, et al. (May 1994). "Possible involvement of central cholinergic system in ameliorating effects of indeloxazine, a cerebral activator, on disturbance of learning behavior in rats". Progress in Neuro-psychopharmacology & Biological Psychiatry. 18 (3): 603–13. PMID 8078992. doi:10.1016/0278-5846(94)90016-7. 
  11. ^ Ogawa N, Haba K, Sora YH, Higashida A, Sato H, Ogawa S (1988). "Comparison of the effects of bifemelane hydrochloride and indeloxazine hydrochloride on scopolamine hydrobromide-induced impairment in radial maze performance". Clinical Therapeutics. 10 (6): 704–11. PMID 3219685. 
  12. ^ Yamamoto M, Shimizu M (July 1987). "Cerebral activating properties of indeloxazine hydrochloride". Neuropharmacology. 26 (7A): 761–70. PMID 3627384. 
  13. ^ Ogawa N, Haba K, Yoshikawa H, Ono T, Mizukawa K (1988). "Comparison of the effects of bifemelane hydrochloride, idebenone and indeloxazine hydrochloride on ischemia-induced depletion of brain acetylcholine levels in gerbils". Res. Commun. Chem. Pathol. Pharmacol. 61 (2): 285–8. PMID 3187197. 
  14. ^ Yamamoto M, Shimizu M, Sakamoto N, Ohtomo H, Kogure K (November 1987). "Protective effects of indeloxazine hydrochloride on cerebral ischemia in animals". Archives Internationales de Pharmacodynamie et de Thérapie. 290 (1): 16–24. PMID 3446040. 
  15. ^ Shimizu-Sasamata M, Terai M, Harada M, Yamamoto M (1993). "Anti-hypoxic and anti-ischemic actions of indeloxazine hydrochloride and its optical isomers: possible involvement of cerebral energy metabolism". Archives Internationales de Pharmacodynamie et de Thérapie. 324: 33–46. PMID 8297184. 
  16. ^ Yamamoto M, Shimizu M (April 1987). "Effects of indeloxazine hydrochloride (YM-08054) on anoxia". Archives Internationales de Pharmacodynamie et de Thérapie. 286 (2): 272–81. PMID 3592867. 
  17. ^ Nakamura J, Anraku T, Shirouzu M, Iwashita Y, Nakazawa Y (June 1993). "Effects of indeloxazine HCl on kindled amygdaloid seizures in rats: comparison with the effects of phenytoin, diazepam, ethanol, and imipramine". Pharmacology, Biochemistry, and Behavior. 45 (2): 445–50. PMID 8327550. doi:10.1016/0091-3057(93)90263-s.